Stefano A Pileri

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Lymphoma classification: the quiet after the storm
    Stefano A Pileri
    Department of Haematology and Oncological Sciences L and A Seragnoli, Bologna University School of Medicine, Bologna, Italy
    Semin Diagn Pathol 28:113-23. 2011
  2. pmc Pathobiology of ALK-negative anaplastic large cell lymphoma
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Pediatr Rep 3:e5. 2011
  3. pmc Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
    C Agostinelli
    Department of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University School of Medicine, Bologna, Italy
    J Clin Pathol 61:1160-7. 2008
  4. pmc New molecular insights into peripheral T cell lymphomas
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 122:3448-55. 2012
  5. doi Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
  6. doi CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified
    Anna Gazzola
    Department of Haematology and Oncological Sciences L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Pathol 64:83-7. 2011
  7. ncbi Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, Hematology and Hematopathology Units, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
  8. ncbi Pathobiology of primary mediastinal B-cell lymphoma
    Stefano A Pileri
    Institute of Haematology Seragnoli, Bologna University, Policinico S Orsola, Via Massarenti 9, 40138, Bologna, Italy
    Leuk Lymphoma 44:S21-6. 2003
  9. doi Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008
  10. doi Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
    Enrico Derenzini
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:1824-9. 2009

Detail Information

Publications39

  1. ncbi Lymphoma classification: the quiet after the storm
    Stefano A Pileri
    Department of Haematology and Oncological Sciences L and A Seragnoli, Bologna University School of Medicine, Bologna, Italy
    Semin Diagn Pathol 28:113-23. 2011
    ..The present review aims to analyse future perspectives after the fourth edition of the WHO Classification released in 2008...
  2. pmc Pathobiology of ALK-negative anaplastic large cell lymphoma
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Pediatr Rep 3:e5. 2011
    ..The main histological findings are illustrated as well as the phenotypic, molecular and clinical characteristics. Finally, the biological rationale for possible innovative targeted therapies is presented...
  3. pmc Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
    C Agostinelli
    Department of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University School of Medicine, Bologna, Italy
    J Clin Pathol 61:1160-7. 2008
    ....
  4. pmc New molecular insights into peripheral T cell lymphomas
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 122:3448-55. 2012
    ....
  5. doi Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
    ..This study investigated the role of immunohistochemical discrimination between GCB and ABC&NC-DLBCL subtypes in identifying those high-risk patients who may benefit from a more aggressive first-line therapeutic approach...
  6. doi CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified
    Anna Gazzola
    Department of Haematology and Oncological Sciences L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Pathol 64:83-7. 2011
    ..CDKN1B/p27, a critical regulator of cell cycle and proliferation, has been suggested to be involved in T cell lymphomagenesis. This study aimed to evaluate the possible occurrence of CDKN1B/p27 aberrations in PTCL/NOS...
  7. ncbi Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, Hematology and Hematopathology Units, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
    ..We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD)...
  8. ncbi Pathobiology of primary mediastinal B-cell lymphoma
    Stefano A Pileri
    Institute of Haematology Seragnoli, Bologna University, Policinico S Orsola, Via Massarenti 9, 40138, Bologna, Italy
    Leuk Lymphoma 44:S21-6. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgV(H) gene crippling mutations...
  9. doi Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008
    ..Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned...
  10. doi Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
    Enrico Derenzini
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:1824-9. 2009
    ..R-MACOP-B regimen followed by involved-field radiation on bulky presentation is safe and very effective in the treatment of young patients with low-risk DLBCL...
  11. ncbi Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Res 67:10703-10. 2007
    ..Our study provides new relevant information on AILT biology and new candidates for possible therapeutic targets such as PDGFRA (platelet-derived growth factor alpha) and VEGF...
  12. doi Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study
    Pier Paolo Piccaluga
    S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 31:3019-25. 2013
    ..We performed a phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype...
  13. doi BCL10 down-regulation in peripheral T-cell lymphomas
    Maura Rossi
    Molecular Pathology Laboratory, Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Hum Pathol 43:2266-73. 2012
    ..In conclusion, BCL10 was commonly down-regulated in peripheral T cell lymphomas, suggest the T-cell receptor signaling cascade for future characterization...
  14. pmc Pathobiology of hodgkin lymphoma
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, 40126 Bologna, Italy
    Adv Hematol 2011:920898. 2011
    ..Treatments adjusted to the pathobiological characteristics of the tumor in at-risk patients have been proposed and are on the way to being applied...
  15. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  16. doi Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive
    Claudio Agostinelli
    Haematopathology Section, Department of Haematology and Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Histopathology 59:679-91. 2011
    ..To revise 25 cases selected from Karl Lennert's personal archive (21) and Bologna and Frankfurt Registries (four) because of cytological similarities...
  17. pmc Prognostic markers in peripheral T-cell lymphoma
    Pier Paolo Piccaluga
    Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Curr Hematol Malig Rep 5:222-8. 2010
    ..The validation process for several models, including clinical-pathological and molecular models, is now ongoing...
  18. doi Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes
    Pier Paolo Piccaluga
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Hematopathology Unit, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Blood 117:3596-608. 2011
    ..In conclusion, our study provided substantial insights on the pathobiology of BLs, by offering novel evidences that may be relevant for its classification and possibly future treatment...
  19. doi Biology and treatment of follicular lymphoma
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Unit, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Expert Rev Hematol 2:533-47. 2009
    ..Novel approaches, including stem cell transplantation, monoclonal antibodies and innovative agents, should be then considered for improving long-term results...
  20. doi Peripheral T-cell lymphoma classification: the matter of cellular derivation
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 4:415-25. 2011
    ....
  21. doi Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples
    Claudio Agostinelli
    Departments of Haematology and Clinical Oncology L and A Seràgnoli, Pathology and Haematopathology Unit, St Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Appl Immunohistochem Mol Morphol 18:561-72. 2010
    ..We describe the newly generated DAK-PAX5 monoclonal antibody raised against a fixation-resistant epitope of the human PAX5/BSAP molecule...
  22. pmc Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 117:823-34. 2007
    ..These results, which might be extended to other more rare PTCL categories, provide insight into tumor pathogenesis and clinical management of PTCL/U...
  23. doi Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody
    Claudio Agostinelli
    Section of Haematopathology, Department of Haematology and Oncological Sciences Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Histopathology 61:33-46. 2012
    ..We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2)...
  24. pmc Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature
    Valentina Tabanelli
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Hematopathology Section, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Med Case Reports 5:218. 2011
    ..abstract:..
  25. ncbi Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:234-44. 2011
    ..For example, the nuclear factor-KB pathway and platelet-derived growth factor receptor inhibition may represent 2 options to be tested in clinical trials...
  26. ncbi Primary cutaneous lymphomas: a reprisal
    Alessandro Pileri
    Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:214-33. 2011
    ..Our aim is to evaluate the commonest types of PCL analysing the clinical characteristics, histology, phenotype, molecular biology, prognosis and therapy...
  27. ncbi Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome
    Stefano Ascani
    Unit of Hematopathology, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Bologna University, St Orsola Hospital, Bologna, Italy
    Haematologica 89:EIM07. 2004
  28. ncbi Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays
    Pier Luigi Zinzani
    Pathologic Anatomy and Lymphoma Unit, Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Haematologica 90:341-7. 2005
    ..Patients with diffuse large B-cell lymphoma (DLBCL) could benefit from integration of well-established bioclinical prognostic factors with new tools - such as micro-arrays - exploring aberrant gene and/or protein expression...
  29. pmc Molecular profiling of aggressive lymphomas
    Maura Rossi
    Molecular Pathology Laboratory, Haematopathology Unit, Department of Haematology and Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Adv Hematol 2012:464680. 2012
    ..In this paper, the authors based on their own experience and the most updated literature review, the main concept on molecular profiling of aggressive lymphomas...
  30. ncbi Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma
    Stefano Ascani
    Unit of Hematopathology, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    J Clin Oncol 22:953-4. 2004
  31. doi Follicular lymphoma: still Six characters in search of an author?
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 52:1655-67. 2011
    ..This review was inspired by the reappraisal of Professor Lennert's personal archive that represents a unique legacy for the entire scientific community...
  32. ncbi Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases
    Cristina Campidelli
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, Unit of Hematopathology, Bologna University School of Medicine, Bologna, Italy
    Hum Pathol 38:787-92. 2007
    ..To the best of our knowledge, the simultaneous occurrence of PTCL unspecified and B-cell small lymphocytic lymphoma is an exceptional event; the possible pathogenetic correlations between the 2 neoplasms are discussed...
  33. ncbi Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
    ....
  34. doi Molecular genetics of peripheral T-cell lymphomas
    Pier Paolo Piccaluga
    Hematopathology Unit, Department of Experimental, Diagnostic, and Specialty Medicine, S Orsola Malpighi Hospital, Pavillon 8, Bologna University Medical School, Via Massarenti, 9, 40138, Bologna, Italy
    Int J Hematol 99:219-26. 2014
    ....
  35. doi Myeloid sarcoma: extramedullary manifestation of myeloid disorders
    Cristina Campidelli
    Unit of Haematopathology, Institute of Haematology and Oncological Sciences L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    Am J Clin Pathol 132:426-37. 2009
    ....
  36. ncbi Granulocytic sarcoma of main biliary ducts
    Stefano Ascani
    Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, St Orsola Hospital, Bologna, Italy
    Br J Haematol 121:534. 2003
  37. ncbi Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients
    Mario Schiavina
    Respiratory Pathophysiology Unit, S Orsola Malpighi Hospital, Via Massarenti 9 40138 Bologna, Italy
    Sarcoidosis Vasc Diffuse Lung Dis 24:39-50. 2007
    ..These observations suggested already in the past a treatment strategy based on hormonal manipulation: discontinuation of estrogens containing medications, avoiding pregnancy, inhibition of estrogens activity and induction of menopause...
  38. ncbi The karma of Kikuchi's disease
    Stefano A Pileri
    Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University School of Medicine, Bologna, Italy
    Clin Immunol 114:27-9. 2005
  39. pmc Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins
    Stefano A Pileri
    Istituto di Ematologia e Oncologia Medica, L e A Seràgnoli Unità Cliniche e di Anatomia Patologica, Universita di Bologna, Bologna, Italy
    Am J Pathol 162:243-53. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations...